Zhongxin Finance, May 23. On the 23rd, Zhijiang Bio released an announcement on abnormal fluctuations in stock trading.
The announcement stated that the company's monkeypox virus nucleic acid detection kit (fluorescent PCR method) is affected by various factors such as market competition, the company's product competitiveness and channel capabilities, and customer recognition, and its sales and profit contributions have a relatively large difference. certainty.
There is uncertainty about the impact of the revenue of the above products in the overseas market on the company's overall revenue.
The announcement stated that the company's stock trading within 3 consecutive trading days (May 19, 2022, May 20, 2022, May 23, 2022) The cumulative deviation of the closing price increase exceeds 30%. According to relevant regulations, it is a stock transaction. Unusual volatility.
After the company's self-examination, the company's current production and operation activities are all normal.
The market environment and industry policies have not undergone major adjustments, production costs and sales have not fluctuated significantly, and the internal production and operation order has been normal.
The World Health Organization has recently reported that more than 12 countries have reported a total of about 80 cases of monkeypox virus.
The company's independent research and development and production (fluorescent PCR method) has been certified by the EU CE, which can help the diagnosis and prevention of related diseases.
Zhijiang Bio said that the company's monkeypox virus nucleic acid assay kit (fluorescent PCR method) is affected by various factors such as market competition, the company's product competitiveness and channel capabilities, and customer recognition, and its sales and profit contributions have a greater contribution. of uncertainty.
There is uncertainty about the impact of the revenue of the above products in the overseas market on the company's overall revenue.
Investors are requested to invest rationally.
On May 23, Zhijiang Bio's daily limit was reported at 49.56 yuan per share, with a turnover of 1.69 billion yuan.
(Finish)